ストックスクリーナーアプリを入手
3.45
0.86%
-0.03
アフターアワーズ：
3.45
前日終値:
$3.48
開ける：
$3.4601
24時間の取引高:
14,428
Relative Volume:
0.10
時価総額：
$248.72M
収益：
$5.15M
当期純損益:
$-65.35M
株価収益率:
-2.5556
EPS:
-1.35
ネットキャッシュフロー:
$-20.85M
1週間 パフォーマンス:
-0.86%
1か月 パフォーマンス:
+21.05%
6か月 パフォーマンス:
+109.73%
1年 パフォーマンス:
+93.82%
1日の値動き範囲:
$3.36
$3.6286
1週間の範囲:
$3.36
$3.79
52週間の値動き範囲:
$1.10
$5.4796
Cellectis Adr Stock (CLLS) Company Profile
CLLS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CLLS
Cellectis Adr
|
3.45 | 349.13M | 5.15M | -65.35M | -20.85M | -1.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Cellectis Adr Stock (CLLS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-03-17 | 開始されました | Bryan Garnier | Buy |
| 2022-05-18 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2022-01-06 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2021-11-30 | 開始されました | JMP Securities | Mkt Outperform |
| 2021-11-08 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2021-10-08 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2021-04-28 | ダウングレード | Guggenheim | Buy → Neutral |
| 2021-03-16 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2020-08-19 | アップグレード | Citigroup | Neutral → Buy |
| 2020-05-12 | 開始されました | Robert W. Baird | Outperform |
| 2020-03-06 | ダウングレード | Goldman | Neutral → Sell |
| 2019-10-30 | 再開されました | Guggenheim | Buy |
| 2019-08-09 | 開始されました | BTIG Research | Buy |
| 2019-05-24 | 再開されました | Citigroup | Neutral |
| 2019-03-14 | 開始されました | William Blair | Outperform |
| 2018-12-19 | 開始されました | Goldman | Neutral |
| 2018-07-16 | 開始されました | Barclays | Overweight |
| 2018-03-16 | 開始されました | Guggenheim | Neutral |
| 2017-09-05 | ダウングレード | SunTrust | Buy → Hold |
| 2017-09-05 | 繰り返されました | Wells Fargo | Outperform |
| 2017-03-02 | 開始されました | Instinet | Buy |
| 2017-02-28 | 開始されました | Wells Fargo | Outperform |
| 2016-04-05 | 開始されました | Ladenburg Thalmann | Buy |
| 2016-03-02 | 開始されました | Sun Trust Rbsn Humphrey | Buy |
| 2015-07-20 | 開始されました | BofA/Merrill | Buy |
| 2015-04-20 | 開始されました | Jefferies | Buy |
| 2015-04-20 | 開始されました | Piper Jaffray | Overweight |
すべてを表示
Cellectis Adr (CLLS) 最新ニュース
European ADRs Dip As Biotech Stocks Tumble In US Trading - Finimize
Barclays Remains a Buy on Cellectis SA (CLLS) - The Globe and Mail
Barclays raises Cellectis stock price target to $8 on promising cancer therapy - Investing.com Philippines
Jefferies raises Cellectis stock price target to $6 after R&D day - Investing.com
Enerpac Tool Group Posts Upbeat Results, Joins Praxis Precision Medicines, J B Hunt, Salesforce And Other Big Stocks Moving Higher On Thursday - Benzinga
Cellectis reports promising data for lasme-cel in r/r B-ALL - Investing.com
Operating cash flow per share of Cellectis S.A. Sponsored ADR – LSX:A14QZE - TradingView
Pre Market Movers: NBTX, IMTX, QNRX See Big Swings - RTTNews
Cellectis’s SWOT analysis: gene therapy firm’s stock poised for growth? - Investing.com
European Pharma And Biotech Companies Led ADR Gains In The US - Finimize
Inventiva, MoonLake Immunotherapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
European Stocks In The US Close The Week Mostly Steady - Finimize
Biotech And Tech Firms Drive Gains For European ADRs - Finimize
European ADRs Dip Slightly As Biotech Stocks Jump And Drop - Finimize
Cellectis Reports Second Quarter 2025 Financial Results & Business Updates - ADVFN Brasil
European ADRs Under Pressure: Sector Divergence and Strategic Entry Points - AInvest
Cellectis’s SWOT analysis: gene therapy firm’s stock faces pivotal moment - Investing.com
Earnings call transcript: Cellectis Q2 2025 earnings miss drives stock down 13% - Investing.com
Cellectis earnings missed by $0.02, revenue topped estimates - Investing.com India
Cellectis earnings missed by $0.02, revenue topped estimates By Investing.com - Investing.com South Africa
European Stocks Dip As US Holders Turn Cautious - Finimize
Unlocking Oncology’s Future: 3 Trending Cancer Biotech Stocks With ‘Strong Buy’ Ratings - Barchart.com
European ADRs Inch Higher As Drugmakers Shine - Finimize
Cellectis shares surge 66% following InvestingPro’s April Fair Value alert By Investing.com - Investing.com India
European Stocks Falter On Wall Street As ADR Index Drops - Finimize
European Equities Slip While Biopharma Stocks Shine - Finimize
European Stocks Shine As ADRs Climb Higher - Finimize
European ADRs Dip With Some Stocks Rising Above The Crowd - Finimize
Cellectis’s SWOT analysis: gene therapy firm’s stock faces pivotal year By Investing.com - Investing.com South Africa
Cellectis’s SWOT analysis: gene therapy firm’s stock faces pivotal year - Investing.com
Cellectis Adr (CLLS) 財務データ
収益
当期純利益
現金流量
EPS
1.62%
0.21%
大文字化:
|
ボリューム (24 時間):